Dan (on for Mitchell Kapoor)

Senior Equity Research Analyst at H.C. Wainright

Mitchell Kapoor is a Senior Equity Research Analyst at H.C. Wainwright & Co., specializing in healthcare and biotechnology companies, with active coverage of firms such as Sarepta Therapeutics, Kerro Therapeutics (KRRO), and MEI Pharma. Kapoor has issued over 340 stock ratings, maintaining a 42.36% success rate and an average return of -7.04%, ranking 2,818th out of 4,918 Wall Street analysts. He has been quoted on major investment calls, including recently adjusting targets for Sarepta and KRRO, and his analyses receive regular institutional attention. Kapoor entered equity research prior to joining H.C. Wainwright, though details on prior employers and professional credentials such as FINRA registration or specific securities licenses were not available from public sources.